SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Regenxbio and NS Pharma evaluate additional RGX-121 data

Regenxbio and NS Pharma are evaluating additional data for RGX-121, according to the market alert, with no catalyst or magnitude supplied.

RGNX

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.